Filana Therapeutics (MEX:FLNA) Total Operating Expense: MXN1,530.91 Mil (TTM As of Mar. 2026)


MEX:FLNA Filana Therapeutics Inc MEX:FLNA
33 GF Score
Price MXN23.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Total Operating Expense?

Filana Therapeutics MEX:FLNA 33 Total Operating Expense is MXN1,530.91 Mil as of Mar. 2026. GuruFocus rates MEX:FLNA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Filana Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was MXN201.39 Mil. Filana Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,530.91 Mil.

Filana Therapeutics Total Operating Expense Related Terms

Filana Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics Total Operating Expense Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 674.25 1,588.57 1,821.90 2,967.33 1,730.82

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 502.99 854.70 217.56 257.27 201.39
MEX:FLNA
33GF Score
Filana Therapeutics Inc MEX:FLNA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,530.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of MXN1,530.91 Mil mean?
Filana Therapeutics (MEX:FLNA) has a Total Operating Expense of MXN1,530.91 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Filana Therapeutics and its competitors.
Is Filana Therapeutics' Total Operating Expense too high?
Filana Therapeutics' current Total Operating Expense is MXN1,530.91 Mil. Overall, Filana Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' Total Operating Expense compare to BOLD and INKT?
Filana Therapeutics' Total Operating Expense of MXN1,530.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Filana Therapeutics and its competitors. Filana Therapeutics's current Total Operating Expense is MXN1,530.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (MEX:FLNA) has a current Total Operating Expense of MXN1,530.91 Mil. The current Total Operating Expense is MXN1,530.91 Mil. Filana Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Filana Therapeutics (MEX:FLNA), the current Total Operating Expense is MXN1,530.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
33GF Score

Get the complete analysis for MEX:FLNA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN23.00
Price